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ABSTRACT 
This thesis deals with different aspects of immune thrombocytopenia disease (ITP), what 
happens before diagnosis, characteristics of patients at treatment start and outcomes 
potentially related to the disease and treatment, such as thrombosis and cancer.  
In study one we investigate the risk of infections prior to the diagnosis of ITP. There are 
some infections causing secondary ITP and there is an association with infection and risk of 
autoimmune disease.  With information from national health registries we were able to 
compare the amount of diagnosis of infection and anti-infective drugs within five years 
before diagnosis of ITP in 1087 patients with primary chronic ITP (cITP) to the general 
population. Our hypothesis turned out to be right and the patients with ITP were more 
likely to have had an infection diagnosis, Standardized Incidence Ratio (SIR) 8.74(7.47-10-
18) and anti-infective drugs SIR 1.37(1.25-1.50) compared with persons of the same age 
and sex in the general population. In addition, we estimated the incidence of ITP in Sweden 
to 2.3 per 100 000.  
In study two we investigated characteristics at treatment start in patients with (cITP). We 
wanted to know how the patients’ characteristics influence start and type of treatment. We 
found that patients start treatment at low platelet counts, median 12(IQR 5-27). This finding 
supports the recommendation to treat in order to avoid symptoms and not aim for a normal 
platelet count, in order to avoid unnecessary potential harm from the treatment. Moreover, 
we confirm that the most common first treatment is corticosteroids followed by diverse 
treatment used as second line treatment and refractory treatment. During the last four years 
of the study splenectomy was less common and the time to splenectomy delayed. 
Comorbidity influenced treatment start and type of treatment. Patients with diabetes were 
less likely to receive corticosteroids. 
 
In the third study underlying risk factors for arterial thrombosis and venous 
thromboembolism were evaluated. In collaboration with a research group at the university 
of Toulouse a cohort study was performed using the same variables and analysis in both 
countries. The incidence rate of arterial thrombosis in France was 15(13.4-16.7) and in 
Sweden 14.7(12.4-17.5) and for venous thromboembolism in France 6.9(5.9-8.1) and 
6.5(5.1-8.1) in Sweden per 1000 person-years, 95% CI. The impact of baseline risk factors 
was similar as well.  
  
 
 In study four we studied the risk of cancer in patients with ITP. Molecular evidence 
suggests that the dysfunctional immune system related to autoimmune disease may increase 
the risk of certain cancers. A risk of haematological malignancies has been reported in 
studies of patients with ITP but the risk of solid tumours warrants further attention and 
those performed have reported contradictory results. We compared the rate of cancer in 
patients with ITP to the general population in a matched cohort study. We found a slightly 
increased risk of overall cancer HR 1.37(1.27-1.48), more pronounced in men, an increased 
risk of liver cancer 3.83(2.46-5.97) and an increased risk of skin cancer after 10 years of 
follow up, 1.52(1.05-2.19). We confirmed the increased risk of haematological 
malignancies. The risk of hematologic malignancies was increased in all time intervals and 
follow a trend with the highest risk, 9-fold, following the year of diagnosis of ITP to down to 
twofold higher 10-20 years after diagnosis We conclude that treating clinicians should have 
a high index of suspicion of cancer when treating these patients. 
  
SAMMANFATTNING  
Avhandlingen behandlar olika aspekter av sjukdomen immun trombocytopeni (ITP): 
händelser före diagnos, patientkaraktäristika vid start av behandling och sjukdomar som 
kan vara associerade med ITP-sjukdom och behandling såsom trombos och cancer. 
I den första studien undersökte vi förekomst av infektioner innan ITP-diagnosen. Några 
infektioner kan ge sekundär ITP och det finns en koppling mellan infektion och risken för 
autoimmun sjukdom. Med information från nationella hälsoregister kunde vi studera 
förekomst av infektionsdiagnoser och infektionsläkemedel inom fem år innan ITP-
diagnosen. Vi jämförde 1087 patienter med primär kronisk ITP med populationen. Vår 
hypotes stämde, patienter med ITP hade fler infektioner Standardized Incidence Ratio (SIR) 
8.74(7.47–10-18) och infektionsläkemedel SIR 1.37(1.25–1.50) jämfört med individer i 
populationen av samma ålder och kön. Vi bestämde också incidensen av kronisk ITP till 2.3 
per 100 000. 
I studie två undersökte vi patientkaraktäristika vid start av behandling för kronisk ITP. Vi 
ville veta hur patientkaraktäristika påverkar start och typ av behandling. Vi fann att 
patienterna har låga värden på trombocyterna vid start av behandling, medianvärde 12(IQR 
5-27). Detta fynd är i linje med rekommendationerna att behandla för att undvika symptom 
och inte sträva efter ett normalt trombocytvärde. Detta för att undvika onödig biverkan av 
behandlingen. Vi bekräftar att den vanligaste behandlingen att starta med är 
  
kortikosteroider följt av olika val vid sekundär och refraktärbehandling. De senaste åren är 
splenektomi mindre vanligt och utförs senare i behandlingsförloppet. Komorbiditeter såsom 
diabetes påverkar behandlingsvalet och färre patienter med diabetes får kortikosteroider. 
I studie tre undersöks riskfaktorer för arteriell trombos och venös tromboembolism. I 
samarbete med en fransk forskargrupp vid Toulouse universitet utfördes en kohortstudie 
med samma variabler och analysmetoder. Incidensen för arteriell trombos i Frankrike var 
15(13.4–16.7) och i Sverige 14.7(12.4–17.5) och för venös tromboembolism i Frankrike 6.9 
(5.9–8.1) och 6.5(5.1–8.1) i Sverige per 1000 personår med 95 % konfidensintervall. 
Således var riskerna lika stora i båda länderna. Påverkan av riskfaktorer såsom 
komorbiditeter var också liknande. 
I studie fyra studerade vi ITP-patienternas risk för cancer. Det finns molekylära 
mekanismer som antyder att den dysfunktionalitet som förekommer i immunsystemet hos 
patienter med autoimmuna sjukdomar kan öka risken för vissa typer av cancer. Det finns 
studier som visat att patienter med ITP har en ökad risk för hematologisk cancer, studier på 
solida tumörer är få och de som finns har visat motsägande resultat. Vi jämförde risken för 
cancer i patienter med ITP mot en matchad kohort i populationen. Vi fann en viss överrisk 
för cancer totalt sett Hazard Ratio 1.37(1.27–1.48 ), mer uttalad i män. Det fanns en ökad 
risk för levercancer 3.83(2.46–5.97) och en ökad risk för hudcancer efter 10 års 
uppföljningstid 1.52(1.05–2.19). Vi bekräftade den ökade risken för hematologiska 
maligniteter. Den risken var ökad i alla tidsintervall, så hög som niofaldig under första året 
efter diagnos, och ner till tvåfaldig efter 10-20 år. Vår slutsats är att behandlande personal 
ska vara uppmärksamma på risken för cancer hos patienter med ITP. 
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Introduction 
Having a chronic disease means having to deal with the consequences of the disease, 
sometimes for the rest of one’s life. It means to suffer from and to be aware of symptoms 
and potential risks linked to the disease, to depend on the effect and safety of drugs for a 
long time, and still maintain an everyday life. The aim of this thesis was to study some 
aspects of the disease immune thrombocytopenia, a disease where the majority of the 
patients develop a chronic disease. Every individual is unique and every patient may have 
certain characteristics that influence the course of the disease and the treatment. Watching 
from a helicopter perspective can make us realize patterns and understand our observations 
better than if it only one observation in one patient is analysed. Epidemiology can be that 
helicopter perspective and bring new perspectives to the clinic. Even though I have only 
read information about these patients in medical records and retrieved information from 
health registers it feels as if I almost know them a little after 10 years “together”. I hope my 
work will be a piece in the puzzle of improving their care. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 10 
The overall aims of the thesis: 
 
Study I. 
To estimate  the incidence of chronic ITP in adults in Sweden, diagnosed between 2007 
and 2011. 
To estimate the ratio of specific infections in patients with ITP compared with the general 
population, other than infections linked to secondary ITP, during a five years’ period before 
the diagnosis of chronic ITP. 
To investigate exposure specific drugs for infection in the year before ITP diagnosis. 
 
Study II. 
To assess predictors of ITP treatment start, in relation to platelet counts and 
characteristics of patients regarding age, sex, co-medication and comorbidity. 
To describe treatment patterns in patients with cITP. 
 
Study III 
To determine the incidence rate of arterial thrombosis and venous thromboembolism in 
patients with ITP in France and Sweden. 
To evaluate the impact of baseline risk factors on the risk of arterial thrombosis and 
venous thromboembolism from national health registries in France and Sweden. 
 
Study IV. 
To analyse the risk of hematologic cancer and solid cancer in patients with ITP compared 
with matched comparators in the general population. 
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1 BACKGROUND, CHAPTER 1 
 
1.1 History of immune thrombocytopenia 
Purpura is the Latin name for purple and is used in medicine to denote skin haemorrhages. 
Disease related purpura was discovered centuries back. One of the important milestones 
was achieved in 1025 when the Persian physician and philosopher Avicenna described 
chronic purpura and several centuries later the clinical definition was proposed and the 
course of ITP described by the German physician Paul Gottlieb Werlhof (1699–1767). The 
disease was named after him and at that point called “Werlhof disease”. In 1951 doctor Dr. 
William J Harrington injected himself with plasma from a patient with immune 
thrombocytopenia (ITP) and developed thrombocytopenia with symptoms, and a 
thrombocytopenic factor in the blood was discovered. Since then ITP has been recognized 
as a thrombocytopenic disease (1, 2). The term platelet (Figure 1) was introduced in 1882 
when the Italian pathologist Bizzozero demonstrated that platelets are an independent cell 
line with a role in thrombosis and haemostasis (3). The understanding of platelet function 
and the ITP-disease mechanisms grow more and more over the years, different research 
groups investigated the disease mechanisms and in the seventies and eighties the binding of 
Immunoglobulin G (IgG) to platelets and megakaryocytes was explained. Several studies 
have reported T-lymphocyte cell abnormalities since the early nineties (4). 
 
Disease definition 
Until 2009 the definition of ITP disease was thrombocytopenia with platelet counts less 
than 150x109/L. The disease was denoted acute ITP if the diseased lasted up to six months 
and chronic if the thrombocytopenia persisted more than six months. In 2009 both the name 
and the definition changed. An international working group decided to change the name 
from Idiopathic thrombocytopenic purpura to Immune thrombocytopenia (ITP) because it is 
established that the disease is autoimmune and not idiopathic and not all patients experience 
purpura. The acronym ITP was kept since it was so well established (5). The definition now 
requests platelets less than 100x109/L since some people can have low platelets in their 
natural state. Starting from 2009 the stages are defined in the following manner: newly 
diagnosed, persistent and chronic (Table 1). The new category persistent was added 
because some patients do not develop chronic ITP and it is not necessary to start heavy 
treatment and splenectomy in those patients who do not develop the chronic form of the 
disease (5).  
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Figure 1. Haematopoiesis, platelet development. 
Free to use from web. https://rbpaonline.com/cell-function-flow-chart/components-blood-article-4/  
 
1.2 Characteristics of Primary ITP disease 
Primary immune thrombocytopenia can be a lifelong disease although some patients do 
experience disease remission in such a degree that they no longer need to be followed in a 
hospital setting. Chronic ITP is often a disease of remission and exacerbation, the severity 
of disease and need for treatment can vary for the same patient throughout the years. 
Symptoms can be both dry bleeding and wet bleeding including excessive bleeding during 
surgery or injury and intracranial bleeding (6) (7, 8). Patients with ITP need extra 
surveillance at dentist interventions, during surgery, pregnancy and delivery. Platelet levels 
can be chronically low and some patients need maintenance therapy in order to keep a safe 
level. It is now consensus that a safe platelet level is a level without risk of symptoms of 
bleeding rather than a normal platelet count level. Normal platelet count levels seem to 
differ between different geographical regions and that is one of the reasons why the 
international working group changed the definition of thrombocytopenia in ITP from 150 to 
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100 *109/L. Studies performed in European countries have reported that a normal platelet 
count for women is around 169–358 *109/ L and for men 143–332*109/L whereas a study 
in Africa showed a lower platelet counts 125-342 x109/ L for females and in male 115-290 
x109/L (15). Platelet counts over 30 *109/L is usually considered safe. Furthermore other 
factors influence the risk of bleeding and accordingly the need for treatment ,such as 
comorbidity, age and lifestyle (5, 6). 
 
Table 1. Primary ITP, definition 
•An autoimmune disease with increased platelet destruction and relatively decreased 
platelet production. 
•Platelets threshold, less than 100 x109/L.  
•Possible causes of the thrombocytopenia has been examined and no cause found.                                                  
•Normal bone marrow or increased amount of megakaryocytes. 
•Symptoms include bleeding which can be dry (e.g. petechiae, hematoma) or wet 
bleeding (e.g. epistaxis, gastrointestinal and intracranial bleeding). 
ITP phases  
•Newly diagnosed less than 3 months. 
•Persistent 3 to 12 months. 
•Chronic over 12 months (5, 6). 
Primary versus secondary ITP  
The disease can be either primary or secondary. Secondary ITP is when the 
thrombocytopenia is secondary to an underlying cause, such as an infection or exposure to a 
drug (Table 2), it is the underlying condition that needs to be treated or the drug that needs 
to be discontinued in order to treat the thrombocytopenia (9, 10).  In other words, it has 
clinical relevance to know if the thrombocytopenia is primary or secondary. The aetiology 
behind primary thrombocytopenia is unknown and the treatment is focused on keeping the 
platelets at a safe level to avoid bleeding. One way to obtain a safe level is by modifying or 
suppressing the underlying immunological reaction in order to inhibit the production of 
autoantibodies or hinder them from attacking the platelets, another is stimulation of the 
production of platelets in the bone marrow (6). 
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Table 2. Causes of secondary ITP 
•Drugs  e.g. heparin and quinidine. 
•Excessive alcohol consumption. 
•Infections: HIV and viral hepatitis (B or C). 
•Haematological malignancies (mainly CLL  and lymphomas ).                              
•Autoimmune lymphoproliferative syndrome type I (ALPS).                                              
•Antiphospholipid syndrome.  
•Autoimmune diseases: Rheumatoid Arthritis, Systematic Lupus Erythematosus, Evans 
syndrome (i.e. ITP and Autoimmune haemolytic anaemia) 
(8),(10) 
1.3 ITP Epidemiology 
A French study reported the incidence according to the new definition to 1.61 per 100 
000/year (11). The estimated incidence (according to the old definition) is in the range 1.6–
3.9 per 100 000/year reported in a systematic review. ITP is more common in the middle 
aged and marginally more dominant in females (ratio 1.2-1.7). Sex differences are not seen 
in children and in the elderly. Most studies about incidence and prevalence have been 
performed in western countries and are not differentiating between different stages of ITP. 
In the systematic review, previously cited, all studies were European, except one, which 
that was from Kuwait (12).  A study from Japan reported an incidence for primary ITP, 
according to the old definition, to be 2.16 per 100,000/year. The difference between males 
and females, was larger than reported elsewhere 1.7 and 2.6, respectively.  
1.4 Aetiology and pathogenesis of primary ITP                                                                                                          
All the blood cells come from a pluripotent hematopoietic stem cell. In the bone marrow 
the megakaryocytes are precursor cells that differentiate into platelets. A lymphoid 
progenitor cell differentiates in the blood to T-cells and B-lymphocytes. The lymphocyte 
cell line is supposed to have a specific attack towards foreign antigen and not an unspecific 
attack towards the body’s own platelet cells, which is the case in the autoimmune reaction 
of ITP (13).The aetiology behind the development of autoimmunity in primary ITP is to a 
large extent unknown. Certain disease mechanisms are known, such as autoimmune 
increased destruction of platelets and reduced production of platelets. ITP is now 
considered a T-helper lymphocyte cell disease characterized by the activation and 
accumulation of T-helper cells (14) (15). The Tregs, T-cells that carry the co-receptor 
protein CD4+, are defect. Considering that these cells differentiate into T-helper cells that 
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activate macrophages and B-cell responses to antigen and other important regulatory 
lymphocytes, this dysfunctionality plays an important role in the loss of self-tolerance in 
patients with ITP (16, 17). The Tregs are decreased and less functioning both in the spleen 
and the circulation (18). Experimental studies demonstrated that Tregs were decreased in 
the spleen in patients with ITP compared with controls (19). Several studies have shown the 
decreased or defective function of Tregs in patients with ITP. These cells suppress the 
activation and proliferation of many cell types including T-cells, B-cells, dendritic cells and 
natural killer cells (NK). The Tregs are important because they control haemostasis and 
immunopathology. Defective Tregs in patients with ITP can be one reason to the loss of 
immunologic self-tolerance and pathogenesis in these patients. In other words, there is 
dysfunctionality in important regulatory cells needed for a functional immune response 
(20). 
The destruction of the platelets is caused by autoantibodies targeting the glycoproteins 
GPIIb/IIIa, GPIb/Ix and GPIa/IIa causing opsonisation of the platelets and phagocytosis of 
macrophages in the spleen. The autoimmune attack from autoantibodies and CD8+ T cells  
directed towards megakaryocytes as well as the TPO hinder a compensation of platelet 
production resulting in thrombocytopenia (18). 
 
1.5 Genes 
ITP is not regarded as an inherited disease. There are a couple of studies that have shown 
similarities in gene expression between unrelated ITP-patients, Single Nucleotide 
Polymorphism, which can give rise to different expression of the gene, arises when there is 
a difference in a single nucleotide in the DNA. Common polymorphisms have been 
reported in the Fc-receptor in unrelated ITP-individuals. The Fc-receptor is located on 
chromosome 1q23-24. The receptor binds to the Fc region on Immunoglobulin G. The 
expression of this gene variant leads to an altered balance of inhibitory and activating 
regulator FcγR on immune cells. Fc gamma is a regulator that activates IgG and the result 
of having this allele (a one base different gene variation) is unbalanced immunity and auto-
inflammation.  In a study comparing 116 patients with ITP to 100 healthy controls the 
FCGR2C-ORF allele was overrepresented among the patients with ITP (18.9% in ITP 
versus 8.8% in healthy controls). The control group had a SNP (Single Nucleotide 
Polymorphism) in the FCGR2C allele as a stop codon so IgG was not activated. The 
conclusion was that the FCGR2C-ORF allele predisposes to ITP (21). 
A Swedish group performed a gene expression study on bone-marrow derived T-cells from 
patients with primary cITP and compared them to non-ITP individuals. The patients with 
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cITP had altered expression in T-cell pathways involved in immune functions necessary for 
a functional immune response. The findings indicate a non-functional immune response in 
bone marrow derived cells from patients with ITP compared with non-ITP individuals (21, 
22).  
Familial aggregation of ITP has been shown.  In a small study, which included paediatric 
patients with a diagnosis of primary ITP, 2.3% of 445l patients had a positive family 
history (23).  
 1.6 Autoimmunity and infection 
How the immune system loses its specificity and starts to turn on its own cells is a 
complicated disturbance in the immune system. In the normal state, the body’s innate and 
adaptive system handles virus and bacteria and when the infection has run its course the 
immune cells decrease and there is no attack on the body’s own cells (13). The 
pathogenesis between infection and autoimmune diseases is not completely clarified. 
Several hypotheses are being evaluated. One of them is the “molecular mimicry”, when the 
antigen mimics a self-peptide, a cross-reaction occurs, and the autoimmune responses is 
directed towards the self-molecule. Another one is “protein changes, cryptic antigens” 
which can happen during infection when antigens that should be recognized as self 
becomes non-self and starts an autoimmune response. “Super-antigens” can trigger a 
number of lymphocytes to react without specific binding. “Bystander activation” is yet 
another mechanism in which where there is epitope-spreading of the antigens resulting in a 
large activation of lymphocytes (24). 
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Fig 1. Autoimmune mechanisms induced by pathogens.  Used with approval of Sfriso P, Ghirardello A, 
Botsios C, Tonon M, Zen M, Bassi N, et al. Infections and autoimmunity: the multifaceted relationship. 
Journal of leukocyte biology. 2010;87(3):385-95. 
 
Previously mentioned, we know from other studies that ITP-patients show alterations in 
genes involved in immune pathways (FCGR2C gene,  IL1RN VNTR and IL2-330) , 
polymorphic genes compared to those of healthy individuals (21, 25). These alterations 
disturb the natural pathway of the immune response and the altered immune response 
cannot handle infections like they should. Dysregulation of T cell activity and cytokine 
abnormalities is a mechanism in active ITP and furthermore contribute to other 
autoimmune diseases. Altered levels of T-helper cell 17-related cytokines are linked to the 
induction of autoimmune diseases like rheumatoid arthritis (RA) as well as in the 
pathogenesis of ITP (26). There are findings of  similar alterations in several different 
autoimmune diseases e.g. ITP, RA and systemic lupus erythematosus (SLE) (27). 
Infection might be a trigger for the autoimmune disease to develop. It could be that the 
patients with ITP have altered immune systems which makes them more susceptible to 
infection both before and after development of the autoimmune disease (28) . 
Apart from the already acknowledged infections such as HIV and Hepatitis C causing 
secondary ITP, studies concerning infections prior to adult ITP-diagnosis are mainly case 
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studies reporting a possible association with candida and pneumonia (29, 30) . However, 
there are some studies regarding infection before autoimmune mediated diseases which 
describe the relationship between infection and disease as being multidirectional. The 
infection alone may not be enough to cause autoimmune diseases but some underlying 
predisposing mechanism makes the patients more susceptible to develop the autoimmune 
disease. An autoimmune disease can be triggered by miscellaneous infections, for example 
SLE can be triggered by Cytomegalovirus (CMV), Epstein Barr Virus (EBV), or Hepatitis 
C virus. It is the same for (RA), which that can be triggered by CMV, Hepatitis C, and 
other infections (24, 31, 32) 
Previous studies have investigated and found that children tend to have infections before a 
diagnosis of ITP. In a prospective multinational study of children, infection was present in 
56% of the patients before the diagnosis of ITP (33). In another study two thirds of those 
with ITP diagnosed had an infection some days to weeks before their ITP-diagnosis and in 
some a particular infectious agent could be directly identified, such as Varicella Zoster 
Virus (VZV), Epstein Barr Virus (EBV), Herpes Zoster (shingles) and upper respiratory 
infections. The characteristic of ITP in children differ from ITP in adults when it comes to 
severity of the disease and whether if it will become a chronic condition or not. Only 20% 
of children with low platelet counts and in contrast to the majority of the in adults 
diagnosed with the acute form of ITP will develop a chronic ITP (34). Infections before the 
onset of ITP in children are VZV, EBV, Herpes Zoster, upper respiratory infections, 
influenza and rubella and (34, 35). Mechanisms like molecular mimicry and cross-reactivity 
causing ITP from Helicobacter Pylori have been suggested and eradication of Helicobacter 
pylori have in some cases helped the patients. In the Swedish guidelines the ITP diagnosis 
includes investigation of Helicobacter Pylori (36) (37) (8).  
 
1.7 Comorbidity 
Primary immune thrombocytopenia is a burden to the patients not only regarding the 
symptoms of the disease and possible adverse effects of the treatment. The persistence of 
the disease can be lifelong and even though the risk of dying from symptoms of the disease 
is considered low, studies still show that the ITP-patients may have a shorter life 
expectancy then the general population; about a 2-fold higher mortality rate. Comorbidity 
with infection, cancer, cardiovascular disease and a more severe ITP disease increases the 
risk (38, 39). The immunosuppressive and cytotoxic drugs used for treatment of ITP along 
with an increased risk of comorbidity can possibly explain the increased risk of untimely 
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death. In a Danish study, where they compared ITP-patients with the general population, 
cause specific mortality in ITP-patients were 1.5 fold higher. The higher rates in the ITP-
patients compared to the general population, ranging from 1.5-5.7, was suggested to be due 
to increased comorbidity with infection, cardiovascular disease, bleeding and 
haematological cancer (40). A speculation is that the immunosuppressive drugs and 
chemotoxic drugs can be involved and may even be the primary cause of untimely death in 
patients with ITP (38) . The increased prevalence of comorbidity, such as cardiovascular 
disease and haematological disease have been reported in other studies (41). The finding 
that the cITP-patients have higher mortality and not related to their risk of fatal bleeding 
makes it important to investigate the role of comorbidity and co-medication in more detail 
and if there is something to be done regarding early detection or treatment management in 
order to improve survival.  
  
1.8 ITP and thrombosis  
Platelets adhere and release activating mediators to release thrombin and the coagulation 
cascade begins. When a similar process occurs at an atherosclerotic plaque it can cause 
occlusive platelets and result in thrombosis. One of the mechanisms is that platelets are 
involved in the pro inflammatory mechanism promoting atherosclerosis. Platelet are 
involved in the immune defence as key mediators off inflammatory processes, releasing 
cytokines among other functions (4). In ITP the platelets are targeted by autoantibodies 
resulting in increased destruction furthermore there is decreased production. In the bone 
marrow the megakaryocytes are increased. Having thrombocytopenia can lead to symptoms 
of bleeding and an excessive amount of bleeding. Thrombosis is a deviation from the 
normal haemostasis that occurs after an injury and bleeding. Apart from the coagulation 
and platelet activation in thrombosis there is clot formation and vessel occlusion that can 
become life threatening (42). Patients with ITP have been found to have increased risk of 
thrombosis, a risk partly linked to their treatment especially to splenectomy (43, 44) even a 
long time after the splenectomy (45). The risk of thrombosis is also associated with 
antiphospholipid (46) (47) (48). Moreover, pro coagulant mechanisms in the platelets of 
patients with ITP compared to non-ITP seem to differ, such as increased plasminogen 
activator inhibitor‐1, which makes the fibrinolysis resistant and possibly causing 
endothelial damage (49) along with other factors that are still unknown. In patients with 
VTE common risk factors for thrombosis and ITP related risk factors such as treatment and 
antiphospholipid are factors to be aware of. The low platelet counts and risk of bleeding in 
ITP does not protect against thrombosis (50). In the clinic it can be hard to balance between 
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protecting the patients from thrombosis and at the same time avoid symptoms of bleeding 
especially in patients with cardiovascular comorbidity. A score has recently been presented 
for clinicians for facilitating the care of these patients (51). 
The median age of diagnosis of ITP is close to 60 years old.  Many patients are likely to 
have comorbidity such as cardiovascular conditions e.g. hypertension and some may need 
to take antithrombotic and/or antiplatelet drugs which may affect their ITP disease and risk 
of bleeding. 
 
2 ITP TREATMENT, CHAPTER 2 
Corticosteroids is the first line treatment in severe or symptomatic ITP (6, 8) and this 
treatment has been used in ITP treatment since the 1950-ies (52). In case of severe 
thrombocytopenia requiring acute treatment where steroids are insufficient or 
contraindicated immunoglobulin infusions (IVIg) are given. This treatment is often 
effective in quickly improving the platelet counts. However, the duration of the effect is 
often short (2-3 weeks) and immunoglobulin may give rare but serious side effects like 
renal insufficiency(6) . 
Platelet transfusion are used rarely as a temporary acute intervention in case of uncontrolled 
bleeding. Corticosteroids in lower doses are commonly used as maintenance therapy, 
sometimes during several years. However, there are some possible adverse effects of 
steroids and some patients do not tolerate them due to problems with sleeping, mania, 
gaining weight, high blood sugar or increase in blood pressure. The immunosuppressive 
function not only hinder the autoantibodies from attacking the platelets but moreover also 
lowers the immune defense with risk of infections. Bone density measurements are needed 
due to risk of osteoporosis when steroids are used for a long time (53, 54).  
About 60-70% have a sustainable response in the form of safe platelet count after treatment 
with splenectomy (55). A major part of platelets and B-lymphocytes are pooled in the 
spleen and antibody bounded platelets are mainly sequestered by the macrophages in the 
spleen explaining the positive effect of splenectomy on the disease (56). The clinical 
challenge is that it is not possible to determine which patients will benefit from a 
splenectomy. The procedure is related to morbidity including chronic pain and porta vein 
thrombosis. Splenectomised patients are at increased risk for infections with pneumococci, 
Haemophilia influenza and meningococcal and need proper vaccination prior to operation 
(43, 57) . 
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Second line treatments other than splenectomy are Thrombopoietin receptor agonists (TPO-
RA) and immunosuppressive agents like Rituximab (anti-B-lymphocyte antibody), 
Azathioprine, Cyclosporine, and cytostatics.  
Rituximab is an anti-B-lymphocyte antibody that can be an effective second line treatment 
and in some patients have a long-term effect (58). However, it is not curative as 
splenectomy can be and has the negative effect of lowered immune defence months after 
treatment and is contraindicated in patients with Hepatitis B. There have been reports about 
rare events of progressive multifocal leukoencephalopathy when using Rituximab in ITP a 
couple of cases have been reported (6, 59). 
Platelet transfusion is only indicated in the temporary treatment of serious bleeding 
manifestation as the effect of this treatment is very short. Symptomatic treatment of 
bleeding manifestations includes local treatment like in epistaxis and systemic treatment 
with Tranexamacid (a fibrinolysis inhibitor) that may help reducing skin mucous membrane 
bleedings.  
The two available thrombopoietin receptor agonists (TPO-RA), Romiplostim and 
Eltrompopag, have mechanisms that increase the production of platelets through binding to 
the thrombopoietin receptor and have shown efficacy in raising platelets). In some patient’s 
platelet counts may fluctuate severely making dose adjustment very troublesome. Adverse 
events include liver toxicity (eltrombopag) and an increased risk for thromboembolic 
manifestations (romiplostim and eltrombopag). Increased reticulin production in the bone 
marrow have been described in some cases but no clinical development to 
myeloproliferative disease have been reported to this date. Long-time follow up studies are 
ongoing. The thrombopoietin agonist function is a mechanism for increasing the cell 
proliferation, a mechanism that could theoretically lead to the uncontrolled cell 
proliferation and malignancies (2). 
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Treatment regimens. (60, 61) 
 First line                                                        
Corticosteroids and immunoglobulin  
 
 Second line 
-Splenectomy 
-Rituximab 
-Thrombopoetinagnoists Eltrombopag or Romiplostim  
-Immunosuppressive used rarely: Azathioprine, Cyclosporin A, 
Cyclophosphamide, Danazol, Dapsone, Mycophenolate mofetil, Vance alcaloids  
 
 Refractory ITP 
Individualized, based on bleeding symptoms, age, activity level. 
-TPO-RA (2, 8) 
-Corticosteroids, intravenous gamma globulin, immunosuppressive agents, 
chemotherapy. 
Platelet transfusion (given at severe bleedings and surgery)(8) 
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3. MATERIALS AND METHODS, CHAPTER 3  
 
Information from the Swedish Health Registers has been used to identify patients with ITP. 
Linkage has been possible using the unique personal identification number (PIN). In 
addition, we have included information from medical records in study II, collected from 
haematology and internal medicine units all over Sweden. In study III I had the opportunity 
to analyse data in the French database Système National des Données de Santé, (SNDS) 
where they are able to link data using the social security number, date of birth and sex. 
 
3.1 DATA SOURCES 
Swedish sources 
3.1.1 The National Patient Register 
The NPR was used to identify patients with codes D69.3 (immune thrombocytopenia) and 
D69.4 (other primary immune thrombocytopenia) from the tenth revision of the 
International Classification of Diseases (ICD-10) to identify adult patients (aged ≥18 years) 
with ITP. Those with two or more ITP diagnoses set at least 12 months apart (62) (63)were 
considered cITP.  
NPR was founded in 1964 and from 1987 includes nation-wide data for all hospital health-
care contacts covering details of hospitalizations such as date and duration of care, 
hospital/department name, surgical procedures and discharge-diagnoses with up to 21 
contributory discharge codes (ICD, 7th–10th). The quality of the register has been shown to 
be of a high standard with almost complete coverage of inpatient care. Furthermore, since 
2001 information on outpatient care has been registered and the coverage increased to a 
national level after a few years. The ICD-codes for different diseases were validated using 
medical records with a positive predictive value of 85-95% (62). 
 
3.1.2 The Prescribed Drug Register 
Information on prescribed drugs was obtained from the Swedish Prescribed Drug Register 
(PDR). The register has been available and linkable to other registers in Sweden since July 
2005. PDR contains detailed information on filled prescriptions including product, quantity, 
dates of prescription and dispensing. The register has complete coverage and high validity 
(64). Drugs administered at hospitals are not recorded which is why we obtained this 
information from medical records in study two. Information about prescribed drugs was 
used to study infection before ITP diagnosis in study one and to study co-medication and 
served as a proxy for disease in study two.  In study four the PDR is used to study co-
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medication and as a proxy for some outcomes. Having both ICD10-codes for diagnosis and 
information about drugs makes the risk of misclassification of a disease less likely. 
 
3.1.3 Total Population Register 
The total population register contains information since 1968. The variables included are 
among others: PIN, date of birth, place of birth, emigration, divorce, marriage, county and 
residency. Furthermore, the register includes the multigenerational register with 
information about parents and siblings, the immigration register (including grounds for 
residence and reason to immigrate) and the PIN register (including PIN changes).  From the 
total population register we retrieved information on emigration and death. We received 
comparison cohorts from the general population(65). 
 
3.1.4 The Swedish Cancer Register 
From the start of the cancer registry in 1958 it has been mandatory to report malignant and 
certain benign tumours to the register, 99% of them are morphologically verified. Regional 
cancer registries are since 1980: ies responsible of the registration helping the health care 
providers and making sure that the information is verified and making sure of a correct 
coding (66). From the cancer register we received information about primary solid and 
haematological cancer.  
 
3.1.5 The Swedish Cause of death register 
The cause of death register holds information about all causes of death since 1911. 
Electronic register based research information is available since 1952. Those who are 
Swedish citizens but died abroad are registered and since 2012 persons who die in Sweden 
but are not Swedish citizens are in the register. In the register there is information about 
residence, place of death, the date of death, underlying cause of death and a contributory 
cause of death (67). 
 
3.1.6 The Longitudinal Integration database for health insurance and labour market studies 
(LISA) 
The LISA register contains variables of socioeconomic (SES) character from 1990 in 
persons older than 15 years of age and from 2010 in patients older than 16 of age and can 
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be obtained from Statistics Sweden. Variables include highest attainable education, 
occupation, disposable income (including income for parental leave, retirement and un-
employment) among other SES (68) (69). 
 
3.1.7 Medical records  
It is obligatory to enter ICD-codes for in and outpatient visits in the NPR and it is 
obligatory and regulated to keep a medical record for each patient (70). In the ethics section 
it is written more about ethics of using medical records for research purposes. The hallmark 
is that a medical record needs to be kept and stored in such a way that is maintained and 
safe from damage and protected in such a way that the secrecy of the patient is protected. 
Only health personnel who is actively involved in treating the patient can read it. With the 
patients consent an external person may be allowed to read it. For research purposes 
sometimes an exception to the rule of consent can be made if there is an ethical approval 
(see Ethical Considerations Chapter 4.) and the interest of the research is more significant 
than a possible violation of the patient’s integrity.  
From the medical records we could retrieve information not found in the PDR regarding 
both inpatient drugs and more detailed information about the prescribed drugs from the 
doctors including real world dates for start and stop dates. The medical records have 
information about when the patients didn't adhere or misunderstood the doctor’s 
prescription. From medical records we collected information about platelet counts, 
leukocytes and haemoglobin and symptoms of bleedings. In comparison with the 
information in the NPR there were a lot more bleedings reported in the medical records, 
including milder bleedings where the patients specifically contacted the hospital because of 
symptoms of bleeding i.e. spontaneous hematoma and petechiae. In the NPR only serious 
bleedings were recorded.  
The collected medical records are part of a longitudinal post authorisation safety study in 
which we are performing safety surveillance of a new drug. This thesis is independent 
academic research without participation of the pharma industry. 
 
French sources  
3.1.8 French database 
The social security system in France started after the end of world war II, in 1945 (71), 
beginning in 1999 legislators proposed the construction of a system enabling health care 
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and drug utilization and gradually the national health insurance system (SNIIRAM) was 
created. The information was first registered for insurance purposes with information about 
in an outpatient visits along with dispensed drugs and drugs for chronic diseases collected 
for the French population (66 million inhabitants). The coverage is nationwide and includes 
employees in private sector, as well as public sectors, students and unemployed. The 
information is now a national health system database used in research with individual 
linkage data from 2009-2017 at this point. 
-Système National des Données de Santé, (SNDS) (72) is the new database from 2016 
covering variables from SNIIRAM but also with the intent to grow and include information 
about cause of death and other parameters and also stores information from: 
-The hospital database: Programme de médicalisation des systems des informations, with 
inpatient discharge diagnoses in all public and private hospitals in France (73); 
-The inter-scheme consumption (Données de consommation inter-régimes - DCIR) that 
contains all outpatient reimbursed health expenditures, including community dispensing of 
reimbursed drugs, as well as chronic diseases allowing full reimbursement that are notified 
by general practitioners (74). 
Diagnoses are coded using the International Classification of Diseases, version 10 (ICD-
10). An anonymous identifier is derived from the social security number of insured 
individuals and can be used for linkage between the registers in the database. The in and out 
patient diagnoses are similarly coded with ICD-10 and procedure codes and dispensed 
drugs with ATC coding. In addition, the French database register chronic diseases in a 
certain register named ALD (Affections de Longue Durée), furthermore they register costly 
drugs given at hospital, which in Sweden is only possible to retrieve in medical records and 
in certain quality registers (72, 75). 
 
4. ETHICAL CONSIDERATIONS, CHAPTER 4  
The study was conducted in accordance to ethical review by the Regional Ethical Review 
Board, Stockholm (Record no 2009/4:10, addendums 2009 1597-31/4, 2009/1597-31/4, 
2013/182-32, 2016/329-32, 2017/53-32 and 20181162-32). 
The studies in this thesis are observational studies where no intervention is taking place. 
The patients are identified in registries by the Swedish National Board of Health and 
Welfare and each patient’s identification number is replaced with a serial number to ensure 
anonymity of individuals. Results are published on aggregated level to prohibit backward 
identification of individual patients. There is a possible violation of integrity when taking 
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part of information from registries and especially when reading the patients’ medical 
records. However, once the data is extracted from the medical record the recording is done 
by using a code which is provided by the National Board of Health and Welfare. An 
exception to having the patients consent can be made for research purposes if the benefit to 
the entire patient group or population is regarded as greater than the potential integrity 
violation in reading a patient’s medical record.  In studies involving human’s ethical 
considerations needs to be taken into account and an approved ethical application is 
required. In observational studies where only health registers are used we expect the 
potential violation of integrity to be small. The violation of integrity of taking part of the 
patient’s information must be weighed against the benefit to the patients with the disease 
and potentially to the general population.   
The ethical approval is required to perform a study and to be able to apply for data. The 
strongest ethical consideration in my thesis is in our study II where we included medical 
records to have more details that we could not find in the registers e.g. lab values. We did 
not ask for the patient’s permission since we identified the patients in the register and we 
could not be sure that the diagnosis code was correct. There is a risk that the worry would 
have been a larger problem than the potential violation of integrity when we read their 
medical records. Only the research group took part of the information and we were only 
observing retrospectively without any attempt to affect treatment or else. According to the 
Swedish Personuppgiftslagen (1998:204)19§, which in May 2018 was replaced by GDPR,  
it was stated that sensitive information can be used for research purposes without informal 
consent from the patients, if the study is approved by an ethical board and only if the 
treatment is necessary and/or the research is necessary and has more bearing than the risk of 
violation of integrity of the patients (76). According to § 20-22, since January 2019, if an 
ethical application is approved, research without consent can be allowed if the study 
participants will not be harmed and the benefit to the patient group is of higher benefit than 
any potential violation of the participants integrity (77) (78). 
France  
The data in France was analysed with the accordance of the Institut des Données de Santé 
in March 2012 (no. 40) and the Commission Nationale de l’Informatique et des Libertés in 
July 2012 (no. DE-2012-076). In the database three and nine variables respectively are used 
to link the different data bases together, only the research group who have applied for 
access to the data and have both ethical approval and approval to work with the data are 
allowed to do so.  
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5. EPIDEMIOLOGY IN HEALTH SCIENCE, CHAPTER 5 
 
5. 1 Epidemiology in health science 
The word epidemiology is an ancient word from the Greek words epi (on or upon) demos 
(the common people) and logy (study) (79). In short, the objectives of epidemiology can be 
characterized as: 
-study the natural course of a disease  
-determine the incidence and prevalence of disease in a population 
-identify patterns and trends of disease occurrence 
-find the aetiology/aetiologies of a disease 
-study the effect and safety of disease prevention and treatment (79). 
 
In epidemiology incidence and prevalence of disease can be investigated and whether or not 
there is a connection between an exposure and an outcome. One of the first epidemiologist 
was doctor John Snow who managed to find out he exposure behind the cholera outbreak in 
London in 1854. He compared cholera mortality between people who got water from 
different sources. Snow found that these people were alike in all other aspects except from 
getting water from different pumps. The factor that differentiated the people who got 
cholera from those who didn’t was that the water passing through London was seeded. This 
is a good example of how looking at a larger picture and comparing people to each other in 
order to find out what can be the cause of an outcome can help identify a problem, however 
this was rather a natural experiment where the participants were not randomly assigned to 
the pumps which would be the case in a clinical trial (80).  
 
5.2 Pharmacoepidemiology 
 Pharmacoepidemiology has had a status as a specific discipline since the mid-1980:ies 
(81). The focus is on the efficacy and safety of drugs (74, 82, 83). Observational 
pharmacoepidemiological studies enables evaluating a more heterogeneous group of 
patients than what is usually included in randomized controlled trials. The benefit of 
observational studies is that they are more suitable for post authorization studies and long-
term follow up and allow for larger cohorts. The disadvantage is that the randomization in 
clinical trials is harder to replicate. 
In order to study drug safety in patients it is useful to perform an observational study in 
order to find out questions like: 
  29 
-the adverse event is in fact an adverse event and not disease progression 
-if there is interaction with other drugs 
-if some patients may be more susceptible to certain adverse events, the events may be 
associated with age, sex, a comorbidity i.e. liver disease or an underlying cardiovascular 
condition (84). 
We strive at comparing patients with similar baseline variables considering age, sex, 
comorbidity and other factor that can have an impact on the outcome.  
 
 With permission from photographer Ulrika Undén. 
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6 STUDY DESIGN AND STATISTICAL METHODS, CHAPTER 6 
6.1 Study design 
In observational studies a cohort study can be the design of choice when one wants to 
examine risk factors for a certain event or several events. The study participants are 
classified as either exposed or unexposed and can be followed to see if an event (or several) 
events occur (85).  A closed cohort can be used if we set the cohort from the beginning, an 
open cohort if there is need for a continuous inclusion of study participants.  The study 
cohort is followed until the time of censor, either the event of interest occurs or one of the 
most common censor variables: death, emigration or end of follow up. All the studies in 
this thesis are cohort studies, in study IV we performed a matched cohort study.  
The case-control can be efficient when studying a rare disease and ITP is a rare disease. 
However, we use nationwide data cohort studies, suitable for rare disease and rare 
outcomes (79). 
6.2 Statistical methods in this thesis 
Standardized Incidence Ratio (SIR) was used in Study I to calculate the ratio between the 
observed rate in the patients with cITP and the rate in the general population. The 
hypothesis is that the patients with cITP have a higher rate of infections than the general 
population. Considering that age and sex are likely to influence the risk of infection we 
calculated the Standardized Incidence Ratio, comparing patients with ITP to the population 
by age and sex. The Standardized Incidence Ratio method is a straight forward way to 
compare what we expected (the calculated rate in the population) to what we observed in 
the patients with ITP and to evaluate the difference by looking at the ratio (86). 
In study II, we described a cohort of cITP patient’s characteristics at treatment start. A 
multinomial logistic regression analysis was used. In multinomial logistic regression we 
can analyse the effect of each independent variable (covariates such as platelet counts, 
bleedings, etc.) on each category of the dependent variable (start of treatment with 
corticosteroids in one category and start of other ITP treatment in the other) compared to 
the reference category, in this case no treatment (87). The method allowed us to compare 
two treatment types to no treatment start in the same model and at the same time include 
several factors and thereby adjusting for several covariates that may have an impact on 
treatment start. Regression is often used when the objective is to study causation, in 
observational studies this is rather an association (88). 
Moreover, a t-test was used to compare the mean time to splenectomy between two time 
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periods by calculating the probability of the observed or a more extreme difference under 
the null hypothesis of no difference (p-value). A t-test is a way to see if there is a 
statistically significant difference between groups (88).  
In study III we performed a cohort study using survival analysis and adjusted for age, sex 
and other relevant covariates (89). In our main analysis we performed a time dependent 
multivariable Cox counting process (90) to estimate associations between risk factors of 
Arterial Thrombosis and Venous Thromboembolism, respectively. All identified 
confounding variables such as age, sex and comorbidities were adjusted for, including time-
varying covariates and fixed covariates. For French and Swedish data, we spent a lot of 
time harmonizing the protocol to make sure that the same variables were included, 
regarding the use of ICD and ATC codes. Furthermore, we verified in what way the 
diagnoses are decided on in order to have the same severity of disease. For the outcomes, 
we restricted to in hospital diagnoses of arterial thrombosis and venous thromboembolism 
to capture only severe outcomes.  
A matched cohort study with 10 comparators from the general population per patient with 
ITP was performed in study IV. To eliminate some factors that could have biased the 
results we matched the patients with ITP to the population by age, sex, calendar year and 
county. Further adjustments were performed regarding comorbidities, number of hospital 
visits as a measure of frailty and socioeconomics (education and income). We performed a 
COX analysis with different time intervals, one year after index, 2-9 years after index and 
10-20 years after index. 
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7. METHODOLOGICAL ISSUES, CHAPTER 7 
 
Internal validity 
A study should aim for having a high internal validity, meaning that measures have been 
taken to have the best possible quality of the study performance. This means starting with a 
thorough literature search, writing a good study plan, choose an appropriate design and 
carefully consider how to deal with missing values, classification, control for confounding, 
selection bias, information bias and other methodological issues.  
External validity 
Generalizability of a study, if the results from the study can be applied in another setting, is 
connected to the external validity. Data from more than one setting can increase the 
external validity of the study.  
Random or systematic errors 
Bias is a systematic error that causes an incorrect (over or under) estimate of an association. 
In observational studies it is important to consider sources of bias and how to deal with 
them. 
Selection bias-If the selection of controls in a study is not randomly sampled nor 
representative of the study base selection bias can be introduced. The comparison between 
cases and controls may then be biased in the analysis. 
Information bias- a bias related to measurement errors, a misclassification. 
Non-differential misclassification is a random information bias when we have no reason 
to believe that the bias effects one group more than another, there is bias due to 
misclassification but exposed and non-exposed are probably affected in the same way. The 
association will be affected towards the null.  
Differential misclassification is a non-random information bias when the information is 
better in one group than another, which can result in an over or underestimation of the 
association.  
Surveillance bias can be present if a group of patients who are followed in a hospital 
setting are compared to a group that are not. The possibility of finding a disease in these 
patients is more likely since the patients are already followed in a hospital setting. There is 
risk of detection bias due to the surveillance of the patients.  
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Reverse causation (Protopathic bias)-The exposure is affected by an underdiagnosed 
occurrence of the outcome as an underlying cause. The exposure-disease process is 
reversed. 
Confounding-a confounder is a variable that affect both the exposure and the outcome. In 
observational studies confounding is always something to consider and aim to control for. 
This can be done at the design stage, such as matching patients with controls. Other tools 
are by restricting e.g. include only women in a study if sex is a confounder. Restricting can 
in some cases introduce bias if the excluded patients or variables have characteristics that 
impact the results (91). In clinical trials randomization is a common way of dealing with 
confounding. At the analysis stage stratification is the most common tool for confounder 
control in cohort studies. A disadvantage of stratification is that we cannot control several 
variables at the same time and moreover there will be fewer persons in each strata and 
when we analyse the data the power in each group is reduced.  
Type I Error 
A significance level of 0.05% is used more often than 0.01% level in observational studies. 
The significance level means that there is a 5% chance of rejecting the null hypothesis even 
though it is true, in other words to commit a type I or alpha error.  
Type II error 
If we fail to reject the null hypothesis even though it is not true we commit a type II or beta 
error. The statistical power is a measure of how well the null hypothesis is correctly 
rejected when in fact the alternative hypothesis is true. Significant testing needs to be 
interpreted with caution (92), a statistically significant result is not always the same as 
being clinically relevant (80, 85, 93). 
Reflection on bias in the studies included in this thesis: 
In study I we considered confounding by age and sex and adjusted for these variables in 
the analysis. We used national registers and had little concern for selection bias. 
Considering that data came from the same source we expect potential measurement errors 
to be non-differential. Infections were measured before diagnosis of ITP, but there was a 
risk of detection bias regarding the diagnosis of ITP. In the sensitivity analysis we 
considered misclassification due to mild ITP and included only those exposed to ITP drugs, 
this did not change the results. We also considered the fact that the patients may have 
started ITP treatment prior to the time when the diagnosis code is set in the register. 
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Therefore, all who had immunosuppressive treatment 30 days before infection or infection 
drug were disregarded. This did not change the results either. 
In study II the risk of misclassification is limited since every medical record is manually 
evaluated before it is classified as cITP. The information in the database where the 
information from the medical record is entered is quality controlled and entering errors 
checked and changed. However, there is risk for missing information, only those who are 
still followed in a hospital setting can be included. There may be loss to follow up for 
patients with a mild ITP disease who are discharged and go on to have their visits in 
primary care.  Considering our aim to study start of treatment this should not be a major 
concern since the patient with chronic ITP are diagnosed in outpatient or inpatient care and 
require at least one year of follow up to have a cITP diagnosis. Possible predictors of 
treatment were included in the analysis and adjusted for. 
In study III There are some unmeasured risk factors such as information about platelet 
counts, genetic risk factors, smoking, immobilization and exposure to ITP drugs. We were 
aware of the risk of misclassification and checked the variables we did include carefully to 
make sure they had the same connotation in order to limit the risk of information bias. We 
adjusted for potential confounding such as age, sex and co-medication in the analysis. The 
risk of selection bias should be limited since we included national databases 
In study IV In order to maintain proportional hazards and because of potential detection 
bias when we compare patients with ITP to the general population we used time intervals in 
the analysis. We matched the comparison cohort to be similar to our patients with ITP in 
the study design, and specified other variables in the model, such as comorbidity, that could 
bias the outcome. Residual confounding remains, we lack certain information in the register 
such as smoking. Information about both patients and matched comparison cohort came 
from the same registers and the bias should be non-differential. 
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8. SUMMARY OF ALL STUDIES. CHAPTER 8 
8. 1 Study I 
Research question: The aetiology behind primary ITP is unknown, causes of secondary 
ITP include other diseases and virus e.g. HIV. Acute thrombocytopenia can follow an 
infection. There are several possible mechanisms to why an infection can be involved in the 
loss of tolerance mechanisms that develop in autoimmune disease. Furthermore, the 
relationship can be bidirectional meaning that the patients with autoimmune disease have 
more difficulty to battle infection. We wanted to investigate if the patients with ITP had 
been exposed to more infections before their disease compared with the general population. 
Since the incidence of chronic ITP has not been determined after the new definition of 
phases of the disease in 2009 we wanted to find out the incidence according to the new 
definition. 
Materials and methods: Information about diagnosis of infection and anti-infective drugs 
was obtained from the Swedish Health Registers. Patients with cITP were included and 
were used to compare the rates of infections between the cITP-patients and the general 
population. The research question was approached using standardized incidence ratios 
(SIR). 
Statistical analyses: Standardized Incidence Ratio adjusted for age, sex and calendar year, 
was calculated to compare the rate of infection between patients with ITP to the rate in the 
general population. The expected number of events was calculated by first adding all 
person-years accumulated in the cohort from the general population, divided into strata 
defined by sex, age (in five-year groups) and calendar year of observation (in 1-year 
intervals). Each stratum specific person-time was then multiplied by the corresponding 
stratum-specific prevalence rate obtained from the entire Swedish population. The 95 % 
confidence intervals (CI) were calculated assuming that the observed events followed a 
Poisson distribution. Some patients may have been treated with immunosuppressant due to 
thrombocytopenia before the ITP-diagnosis was recorded in the register. To minimize the 
risk of misclassification and rule out that the infection was due to the immunosuppressant 
drug a sensitivity analysis was performed where all infections and anti-infective treatment 
that were recorded within 30 days after an immunosuppressant therapy were disregarded. 
As an additional sensitivity analysis, we included only those patients with cITP who 
received ITP-treatment in order to exclude those with an ITP at subclinical level. SAS 
statistical software version 9.4 (SAS Institute, Cary, NC, USA) was used to analyse the 
data. 
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Results and discussion 
Main results (all results in paper I page 809-811). 
Time period                                                                                                               2009-2014 
Number of cITP patients:                                                                                                   1087 
                            Female                                                                                          556 (51%) 
Time period                                                                                                               2009-2014 
The incidence of patients with cITP                                               2.3 (2.15-2.45) per 100 000 
Mean age at cITP diagnosis, years                                                                                         57  
                             Female:                                                                                       54 (SD 21) 
                             Male:                                                                                            61(SD 20) 
All infections, diagnosis                                   Observed 167 Expected 19 SIR 8.7 (7.4-10.1)  
Female                                                                                                         SIR 11.1(8.8-13.9) 
Male                                                                                                            SIR 7.36 (5.9-9.05) 
All anti-infective drugs                                     Observed 474 Expected 347 SIR 1.4 (1.3-1.5) 
Antibacterial drugs or systematic use                      Observed 435 Expected SIR 1.3 (1.2-1.5) 
 
Discussion: The patients with primary cITP had an increased rate of infections within five 
years before diagnosis of ITP compared with the general population of the same age and 
sex. Considering the bidirectional relationship between autoimmune disease and infection 
this can have a biological explanation. In autoimmune disease the dysregulation of the 
immune system makes it more difficult to take care of pathogens (28). An association 
between infection and other autoimmune disease such as autoimmune thyroid disease and 
systematic lupus erythematosus have been reported (31, 94). This is important knowledge 
considering the aetiology of ITP is still unknown and because treatment for ITP is 
immunosuppressive or immunomodulatory. A limitation to the study is that we did not 
adjust for confounders other than age and sex, comorbidity might have an impact. 
However, the difference was quite large and if we assume that the bias from comorbidity is 
non-differential the higher ratio of infection needs to be considered. ITP is a diagnosis of 
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exclusion and sometimes the patients receive ITP-treatment before the diagnosis code is 
registered. A sensitivity analysis was performed to exclude those with an anti-infective 
treatment a month before ITP. An additional sensitivity analysis was performed to include 
only more severe ITP patients who received ITP-treatment. The results did not change in 
these analysis.  
8.2 Study II 
Research question: There are no guidelines only recommendations for treating patients 
with ITP and several articles point out that evidence based studies are warrant. We were 
interested to perform a study on real-world data to see the clinical practice of ITP treatment. 
The hypothesis was that the patients are treated to avoid symptoms rather than receiving 
prophylactic treatment and maintain a normal platelet count. We were interested in how 
patient characteristics influence start of treatment. 
Materials and methods: Adult patients with chronic ITP from 2009-2016. National Health 
Registers and medical records.  
Statistical analyses: Characteristics of the study participants including time since first ITP 
diagnosis to start of treatment, platelet count during 10 days preceding start of treatment, 
comorbidities during 90 days preceding start of treatment, co-medications during 90 days 
preceding start of treatment and duration of treatment were shown using descriptive 
statistics such as numbers, mean, median and proportions. Frequency distributions for 
categorical variables were generated.  
We predicted treatment start by using a multinomial logistic regression to calculate the odds 
ratio for the different patient characteristics. We investigated the same factors in the model 
as in the descriptive analysis. The multinomial logistic regression allowed us to have two 
outcomes in the model with two different treatments (corticosteroids and other ITP 
treatments)and no treatment start as reference. 
Main Results. All results in paper II: In a cohort of 858 patients with cITP the patients’ 
start treatment at relatively low platelet counts, median platelet counts 12*109/L. Severe 
bleedings are present in 75 (13%) at treatment start. Co-medication influence treatment 
start, patients with diabetes were less likely to start treatment with corticosteroids and 
patients with antihypertensive drugs had higher odds of starting treatment. Corticosteroids 
are the most common treatment in 537(92%) of the patients. In figure 3 the distribution of 
therapeutic drugs and splenectomy after initial corticosteroid treatment is shown. 
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Figure 3. Second treatment given after corticosteroids.  
Discussion: Our study gives real-world evidence study to the recommendations to treat in 
order to avoid symptoms rather than aiming for a normal platelet count, and avoid 
unnecessary treatment. Among the patients with severe bleedings a majority of them had 
comedication with antithrombotics and antiplatelets. Previous studies have found platelet 
counts in line with ours (95) (96)and an increased risk of bleeding in patients above 80 
years of age (97). Including both medical records and information from the register helped 
us answer the research question about characteristics at start of treatment and the impact 
from comorbidities (i.e. diabetes) on treatment start. It was especially important to have 
information on platelet counts and milder bleedings such as hematoma and epistaxis which 
is rarely reported in the NPR but remains problematic symptoms for the patients. We had a 
good representation of hospitals from smaller to large university hospitals but lacked 
information from primary care. However, the diagnosis is generally from a hospital setting 
and we focused on treatment start in incident patients.  
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8.3 Study III 
Research question: Our hypothesis was that not only rate of venous thromboembolism 
moreover the rate of arterial thrombosis is increased in patients with ITP and we were 
interested to know if and if certain risk factors other than age, sex, comorbidities and co 
medication might have an impact on the rate.                                                                    
Materials and methods: Two nationwide registers, similar ICD-codes and ATC-system in 
both countries investigate baseline covariates and risk of AT and VTE in patients with 
primary ITP of all stages. 
Statistical analyses: We included all patients identified with an ITP diagnosis during the 
study period and estimated incidence rates of AT and VTE, first in the overall ITP 
population in each country, and then by baseline risk factors. Patients with the risk factor at 
baseline were compared with patients who did not have the risk factor. We performed a 
cohort study using a COX survival analysis and adjusted for age, sex and other relevant 
covariates (14). In addition, we performed a sensitivity analysis in which we adjusted for 
age and sex. In our main analysis, we performed a time dependent Cox counting process 
where all identified confounding variables were adjusted for, including both time-varying 
covariates and fixed covariates. In the Cox counting process the data is split in different 
time intervals and all covariates are taking into account in the analysis. 
 
 
 
 
 
 
 
 
 
 
 
 40 
 
 Main results, all results in paper III pages 126-129: 
Arterial Thrombosis 
ARTERIAL  
THROMBOSIS 
SWEDEN 
 
FRANCE 
 
Number of patients     2490                       7225 
Incidence of AT.       
with 95% CI                14.7 (12.4-17.5)    15.0 (13.4-16.7) 
Multivariable analysis, HR with CI 95% 
Sex, ref male 
 
0.7 (0.5-1.0) 
 
0.5 (0.4-0.7) 
Age groups,  
18-39 
40-59 
60-74 
>=75 
 
Ref 
5.8 (1.2-28.5) 
25.1 (6.0-105.0) 
75.4 (18.1-314.4) 
 
Ref 
8.4 (3.2-22.2) 
19.7 (7.5-51.3) 
18.6 (7.1-48.7) 
History of AT 
3.1 (2.0-5.0) 2.5 (1.8-3.5) 
Antiplatelet drugs 
1.4 (0.6-3.2) 1.6 (1.2-2.1) 
Kidney disease 
2.6 (1.2-6.0) 1.2 (0.9-1.7) 
              https://pixabay.com/sv/vectors/sverige-flagg-karta-land-europa-880120/ 
              https://pixabay.com/sv/illustrations/search/karta%20%C3%B6ver%20frankrike/ 
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             Venus thromboembolism 
VENOUS 
THROMBOEMBOLISM 
SWEDEN 
 
FRANCE 
 
Incidence of VTE, 
with 95 % CI 
6.5 (5.1-8.4) 6.9 (5.9–8.1) 
Multivariable analysis, HR with 95% CI 
Sex, ref male 
0.9 (0.5-1.6) 1.2 (0.9-1.7) 
Age groups,  
18-39 
40-59 
60-74 
>=75 
 
Ref 
2.5(0.6-10.4) 
5.6 (1.6-19.8) 
15.0(4.2-54.0) 
 
Ref 
1.9 (1.1-3.4) 
2.3 (1.3-4.0) 
3.5 (2.1-6.0) 
History of VTE 
13.5 (5.5-33.4) 3.5 (0.8-14.2) 
Cancer 
0.6 (0.2-2.0) 1.8 (1.2-2.7) 
               https://pixabay.com/sv/vectors/sverige-flagg-karta-land-europa-880120/ 
               https://pixabay.com/sv/illustrations/search/karta%20%C3%B6ver%20frankrike/             
Discussion: The finding of similar rates of arterial thrombosis and venous 
thromboembolism in France and Sweden strengthen the finding of a higher rate compared 
with a general population. Previous studies report that thrombocytopenia does not mean a 
lower risk of thrombosis (38, 98). The finding is important considering the median age of 
ITP is almost 60 years of age, the patients are expected to have comorbidities. Co-
medication with antiplatelet and antithrombotic drugs indicate an underlying cardiovascular 
disease and is an additional risk factor for thrombosis in the patients with ITP. 
Comorbidities are important to take into consideration when evaluating the risk of bleeding 
and thrombosis and a score for helping clinicians had been proposed (51). A high index of 
 42 
suspicion of both arterial thrombosis and venous thromboembolism is warrant in treating 
these patients, while carefully evaluating their risk of bleeding. In a future study it would be 
of interest to include ITP treatment. Considering IVIg, romiplostim and rituximab are given 
at the hospital and not included in the Swedish Prescribed Drug register (available in the 
French registers) this would require medical records.  
  
8.4 Study IV 
Research question: An increased risk of haematological malignancies have been associated 
with ITP in previous studies. Solid tumours are not so investigated apart from a few studies 
where stomach cancer has shown contradicting results. There are molecular mechanisms 
involving the loss of tolerance that may be involved in a less strong way to attack tumour 
antigens that can lead to the suspicion of an increased risk of tumour development in 
patients with autoimmune disease. 
The NPR was used to identify comorbidities and the Charlson comorbidity index 
calculated. Moreover, amount of in and out hospital visits was defined. The general 
population comparison cohort was randomly selected by the TPR and matched on age, sex 
and calendar year.  
Materials and methods: Matched-cohort using the Swedish National Health registers to 
compare adult patients with ITP of all stages (newly diagnosed, persistent and chronic) to 
controls from the general population matched on age, sex, county and calendar period in 
study period 1997-2016. 
Statistical analyses: First we calculated incidence rates and incidence rate ratios between  
the patients with ITP and the matched cohort. We compared the impact by covariate on 
each cancer outcome. In the main analysis we investigated if the patients with ITP have 
higher rates of overall and organ specific cancers compared with the matched comparison 
cohort from the general population. Cox proportional hazards regression was used to 
estimate the risks. The underlying time scale was the follow-up time from diagnosis of ITP 
or index date for the comparison cohort. We used time split in three categories first year, 2-
9 years and 10-20 years in order to keep proportional hazard in the model and to be able to 
identify possible detection bias. A comparison cohort from the general population were 
matched by sex, age groups, socioeconomic index and residential place. 
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Figure 4. Hazard Ratios (HR) for cancer in patients with ITP compared with the matched 
cohort in time intervals. Adjusted for age, sex, residential place, index year, Charlson 
comordity index score, number of hospitalizations and outpatient care visits, income, 
education. 
Results: The mean follow-up time after diagnosis of ITP was seven years (standard deviation 
5.1. The number of patients with primary ITP were 6 740 (55% women) and 59 394 (55% 
women) persons in the matched comparison cohort. The incidence rate ratio (IRR) of overall 
cancer in patients with ITP was 1.45 (95% CI 1.35-1.56). The main results of the study are 
presented in Figure 4 and 5. The hazard ratios at different time intervals (first year, after 2-9 
years and after 10-20 years) for haematological cancers are presented in Figure 4. In Figure 5 
hazard ratios for any cancer, cancer in the digestive organs as well as site-specific cancers are 
presented in time-intervals. 
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Figure 5. Hazard Ratios (HR) for digestive tract cancer in patients with ITP compared 
with the matched cohort in time intervals. Adjusted for age, sex, residential place, index 
year, Charlson comordity index score, number of hospitalizations and outpatient care 
visits, income, education. 
Discussion: We confirmed an increased risk of haematological malignancy in patients with 
ITP compared to the general population (99-102). The risk is important knowledge 
regarding the surveillance of the patients. Some patients with ITP have a mild disease and 
are discharged from follow up since their thrombocytopenia is regarded mild.  Is the risk of 
haematology malignancies related to severity of the ITP disease? Future studies are 
warrant; it could be of importance to see whether or not all patients with ITP may benefit 
from continuing their surveillance considering the increased risk of hematologic 
malignancies.  
The graph above shows that the increased risk for most cancer diagnosis is more 
pronounced the year following diagnosis of ITP, liver cancer is more pronounced after 2-9 
years. After adjusting for sex, age, socioeconomics, comorbidities and number of hospital 
visits we found an increased risk of solid tumours in patients with ITP compared to the 
general population, more pronounced in men. Certain cancers (ovarian, brain and large 
intestine) were only increased during the first year following diagnosis of ITP which can be 
considered as a probable detection bias. The patients are thoroughly investigated due to 
their ITP and early symptoms and abnormal lab values indicating cancer can be detected. 
Liver cancer and skin cancer were still increased years after diagnosis which is more of a 
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signal of an increased risk in these patients. The result is of importance regarding 
surveillance of these patients and when developing and evaluating new drugs. When we 
interpret the result of an increased risk in liver cancer in males with ITP we tried at first to 
adjust for alcohol use. There were too few registered events of alcohol dependency and 
liver disease due to alcohol in the register to be able to adjust for it, however alcohol related 
thrombocytopenia is defined as secondary ITP and when the primary ITP diagnosis is given 
excessive alcohol drinking is usually ruled out. There are certain activity of destruction of 
platelets by antibodies not only in the spleen but also in the liver that separates the patients 
with ITP from non-ITP (103), the mechanisms in relation to cancer needs more evaluation. 
 
9. DISCUSSION, CHAPTER 9 
9.1 Strengths 
The observational studies performed in this thesis have the advantages of limited selection 
bias, long follow up and no recall bias. The strengths of these studies include the population 
based design and the possibility to include register data for all patients with primary ITP 
during the study period. This means there is limited risk of selection bias of a certain group 
with particular characteristics. We obtained information on both inpatients and outpatients, 
to identify all hospital contacts during the study period. The accuracy of diagnoses recorded 
in the Swedish Patient Register is generally high (62). Moreover, we used data from the 
PDR which provides information on all dispensed pharmacological treatments. In study I 
and IV the comparison group is the Swedish general population, in study IV ten matched 
controls from Statistics Sweden, limiting the selection bias. However unmeasured 
confounders can never be completely ruled out. 
In addition, in study II we have medical records which contains detailed information not 
found in registers including blood values and treatment received at the hospital increasing 
the internal validity of the study when such detailed information can be used. Furthermore, 
I am very familiar with the data after 10 years of abstracting medical records from patients 
with ITP. Every year the data is quality controlled for data entry mistakes which the data 
abstractors correct and if we lack data we collect it continuously, ensuring a high quality of 
the collected data from the medical records. Even with national registers Sweden is a small 
country when studying details about a rare disease. Even though we didn’t pool the data in 
study III the findings in our study is strengthened with the data from another country and 
with the similar results. In particular, such a large country as France with 66 million people 
included in a linkable database. Furthermore. the fact that both countries had the same 
variables and that we used the same analysis in both databases, increased the internal 
validity.  
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9.2 Limitations 
The current studies have some limitations. The lack of primary care data is a limitation 
because patients may have follow up visits in primary care and we lack access to this 
information. We have information from the PDR on all pharmacological treatments 
prescribed from primary care that are dispensed. But there is no indication for treatment and 
for the studies with chronic ITP we lack medical records from primary care, so there is risk 
of loss to follow up for those patients, most probably when the cITP disease is milder. We 
also lack information from cITP patients who are only treated for their ITP at another clinic 
i.e. obstetrics. There might be more patients with mild ITP who never seek medical care 
even though they might have thrombocytopenia. In common with other registry studies 
from Sweden (apart from certain quality registers) we lack information about drugs given at 
hospital. Fortunately, we had collected medical records and were able to use the 
information to analyse start of treatment and treatment pattern in study II. 
 
9.3 Conclusion: Findings and implications 
I. In study I we reported the incidence of cITP and an increased rate of several 
infectious diseases prior to the diagnosis of ITP. This has implications 
considering that patients with ITP are often treated with immunomodulatory 
treatment and the finding may be a mechanism in the dysregulated immune 
system of autoimmune patients. We did not find a new cause of a secondary 
ITP but contributed to the scientific evidence that there is an association 
between infection and ITP.  
II. In study II we were interested to describe the patients with ITP more in 
detail and learn about their treatment pattern and start of treatment since 
previous studies had questioned how severe their symptoms were in relation 
to treatment. We observed that their treatment started at low platelets and 
that co-medication such as antihypertensive drugs and diabetes influenced 
the treatment decisions. Platelet counts below 20*109/L, antihypertensive 
treatment and bleedings were the strongest predictors of treatment start and 
diabetes yielded lower odds to start corticosteroid treatment. In the latter 
years’ splenectomy is less common and time to splenectomy delayed. There 
was a call for evidence based studies in this field. We contributed with a 
scientific investigation with detailed information from both registries and 
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medical records about characteristics of treatment start, which can be 
informative for clinicians treating patients with ITP. 
III. In study III we investigated the impact of comorbidity on the rate of AT and 
VTE in patients with ITP in two national databases We found that age and 
male sex are the most important risk factors for AT and age for VTE. 
Baseline risk factors increase the risk later on.  When treating patients with 
ITP, the occurrence of risk factors associated with the disease and with 
thrombosis, should be acknowledged. The results from two nationwide 
studies have similar results regarding the rate of AT and VTE, giving 
evidence to the importance of being aware of an increased risk of AT and 
VTE which of course is important for clinicians, especially in an elderly 
population with comorbidities. 
IV. Risk of cancer in patients with ITP.  We can confirm that the risk of 
hematological malignancy is increased in patients with ITP compared with 
the general population. The results from our investigation of the most organ-
specific cancers revealed an increased risk of liver cancer and skin cancer in 
ITP compared to the general ppopulation several years after diagnosis of 
ITP. 
 
 Summary of the main findings and implications in this thesis: 
In this thesis incidence of patients with primary chronic ITP in Sweden were reported. The 
main findings are that even though the ITP disease seems quite mild in terms of symptoms 
of severe bleedings and we learnt that asymptomatic patients can fact be left untreated there 
are other factors complicating the disease outcome. We found that the patients with ITP 
have a susceptibility to infections prior to the diagnosis of ITP and an increased risk for 
both arterial and venous thromboembolisms. We conclude that clinicians need to have a 
high index of suspicion for cancer (haematological malignancies, liver and skin cancer in 
particular), risk of infections and thrombosis in patients with ITP. 
9.4 Future perspectives  
 The incraesed risk of cancer needs to be be further investigated with respect to 
severity of ITP disease and exposure to ITP drugs.  
 
 There is need for more knowledge about how patients with ITP are affected in their 
everyday life, by the disease itself and due to the treatment. There are previous 
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studies reporting that patients with ITP have problems with fatigue and that they are 
staying away from social activities. A survey study should be performed. At the 
same time information about experience of adverse-events, especially milder 
adverse events of drugs could be collected. These kind of studies are lacking.  
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